Synchron

10 articles with Synchron

• Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US

  7/28/2021

  Synchron, a venture-backed brain data transfer company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application for its flagship product, the StentrodeTM motor neuroprosthesis.

• 

  Money on the Move: June 2-8

  6/9/2021

  Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week.

• Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface

  6/3/2021

  Synchron, a brain interface platform company , today announced that the company has secured $40M in a eries B round of financing led by Silicon Valley venture capital firm Khosla Ventures.

• Synchron’s Stentrode Brain-Computer Interface Receives Breakthrough Device Designation from FDA

  8/27/2020

  Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials

• Synchron Achieves First Successful Human Implantation of Brain Computer Interface

  9/20/2019

  Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive neural interface technology, a component of the Synchron Brain-Computer Interface.

• Synchron Initiates First-ever Clinical Trial to Evaluate Thought-to-Text™ Brain-Computer Interface Technology in Patients with Severe Paralysis

  4/8/2019

  Royal Melbourne Hospital study evaluates ability of minimally-invasive Stentrode™ neural interface technology in combination with BrainOS™ to restore communication in patients with severe paralysis due to stroke, motor neuron disease, ALS and spinal cord Injury

• Study Published in Nature Biomed Shows Promise for Patients with Neurological Conditions including Parkinson's disease, Depression and Epilepsy

  12/3/2018

  Synchron Inc., a company developing minimally invasive neural interface technology, today announced data demonstrating the feasibility of minimally-invasive techniques to enable focal brain stimulation has been published in the journal Nature Biomedical Engineering

• Synchron Secures $10 Million In Series A Financing Round

  4/4/2017

• Endovascular Start-up Synchron Appoints Neurovascular Veteran Martin Dieck as Chairman

  4/21/2016

• BioTrove, Inc., Synchron Team Up for European Customer Solutions

  5/6/2008